The A-Mab Case Study is a landmark industry document developed by the CMC Biotech Working Group to demonstrate how Quality by Design (QbD) principles can be applied to the development and manufacturing of a monoclonal antibody (mAb). Released in 2009, it serves as a comprehensive roadmap for navigating the complex journey from laboratory discovery to large-scale commercial production. Core Objectives of the A-Mab Study
The development of a monoclonal antibody (mAb) bioprocess is a complex and challenging task. Monoclonal antibodies are a class of therapeutic proteins used to treat a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. The bioprocess development of a mAb involves several critical steps, including cell line development, fermentation, purification, and formulation. In this case study, we will explore the bioprocess development of a model mAb, "A Mab," from cell line development to commercial-scale production. A Mab A Case Study In Bioprocess Development
Risk Assessment: Using prior knowledge and failure mode effects analysis (FMEA) to identify process parameters that most significantly affect CQAs. The A-Mab Case Study is a landmark industry
CEX Step: Mab-X binds to a strong cation exchanger (Poros 50 HS) at pH 5.5. The team runs a shallow salt gradient (0 to 150 mM NaCl over 30 column volumes). This resolves the main peak from the deamidated variant, which elutes slightly earlier. Collection windows are narrowed to 70-85% of peak height, discarding tails. Cell line instability: The CHO-A Mab cell line